Tommaso Bianchelli

Tommaso Bianchelli

Auto-generated profile, based on publicly available information

Tommaso Bianchelli

Dermatology Unit Istituto Nazionale di Riposo e Cura per Anziani INRCA‐IRCCS Hospital Ancona Italy

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 May 2020 in Journal of Medical Virology
Verified
Journal Article
Closed access
PDF file
FDFederico Diotallevi
Federico Diotallevi
ACAnna Campanati
Anna Campanati
TBTommaso Bianchelli
Tommaso Bianchelli
IBIvan Bobyr
Ivan Bobyr
MLMIchele Luchetti
MIchele Luchetti
AOannamaria offidani
annamaria offidani

13 December 2023 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Closed access
AMA. Marani
A. Marani
TBT. Bianchelli
T. Bianchelli
RGR. Gesuita
R. Gesuita
AFA. Faragalli
A. Faragalli
CFC. Foti
C. Foti
COCollaborators
Collaborators

6 February 2023 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Closed access
EPElena Pezzolo
Elena Pezzolo
MRMariaTeresa Rossi
MariaTeresa Rossi
FCFrancesca Caroppo
Francesca Caroppo
TBTommaso Bianchelli
Tommaso Bianchelli
Anna Belloni FortinaAnna Belloni Fortina
Anna Belloni Fortina
LNLuigi Naldi
Luigi Naldi

20 August 2024 in Journal of Dermatological Treatment
Verified
Journal Article
Open access
DOD. Orsini
D. Orsini
MMM. Megna
M. Megna
CAC. Assorgi
C. Assorgi
ABA. Balato
A. Balato
RBR. Balestri
R. Balestri
ADA. Dattola
A. Dattola
Purpose of the article: The aim of this multicenter observational study is to report data from real world on the use of bimekizumab in patients aged ≥ 65 years with moderate-to-severe plaque psoriasis. Elderly patients are poorly represented in clinical trials on bimekizumab for plaque psoriasis, and real-world studies are important to guide clinical choices. Materials and methods: A retrospective multicenter study was conducted in 33 dermatological outpatient clinics in Italy. Patients aged ≥ 65 years, with moderate-to-severe plaque psoriasis and treated with bimekizumab were enrolled. No exclusion criteria were applied. Bimekizumab was administered following the Italian Guidelines for the management of plaque psoriasis and according to the summary of product characteristics, in adult patients who were candidates for systemic treatments. Overall, 98 subjects were included, and received bimekizumab up to week 36. Clinical and demographic data were collected before the initiation of treatment with bimekizumab. At baseline and each dermatological examination (4, 16, and 36 weeks), clinical outcomes were measured by the following parameters: (1) PASI score; (2) site-specific (scalp, palmoplantar, genital, nail) Psoriasis Global Assessment (PGA). At each visit, the occurrence of any adverse events (AEs) was recorded, including serious AEs and AEs leading to bimekizumab discontinuation. Results: The mean PASI score was 16.6 ± 9.4 at baseline and significantly decreased to 4.3 ± 5.2 after 4 weeks (p < 0.001), and 1.1 ± 1.7 after 16 week (p < 0.001). This level of improvement was maintained after 36 weeks (p < 0.001). PASI ≤2 was recorded in 36 (36.7%) at week 4, 68% and 69.4% at week 16 and 36, respectively. By week 16, 86/98 (87.8%) patients reached PASI75, 71/98 (72.4%) obtained PASI90, and 52/98 (53.1%) PASI100. Binary logistic regression tests showed a significant association of PASI100 by week 4 with lower PASI at baseline. PASI 100 at 16 or 36 weeks was not associated with baseline PASI, obesity, age, gender, previously naïve state, and presence of psoriatic arthritis. Patients naïve to biologics at baseline had similar response to bimekizumab as non-naïve subjects. Conclusions: Bimekizumab is a suitable option for elder patients as it is effective, tolerated and has a convenient schedule.

31 December 2020 in Current Pharmaceutical Biotechnology
Verified
Journal Article
Closed access
PDF file
EMEmanuela Martina
Emanuela Martina
FDFederico Diotallevi
Federico Diotallevi
TBTommaso Bianchelli
Tommaso Bianchelli
MPMATTEO PAOLINELLI
MATTEO PAOLINELLI
AOannamaria offidani
annamaria offidani
Background: Chronic Spontaneous Urticaria (CSU) is a disease characterized by the onset of wheals and/or angioedema over 6 weeks. The pathophysiology for CSU is very complex, involving mast cells and basophils with a multitude of inflammatory mediators. For many years the treatment of CSU has been based on the use of antihistamines, steroids and immunosuppressive agents with inconstant and frustrating results. The introduction of omalizumab, the only licensed biologic for antihistamine- refractory CSU, has changed the management of the disease. Objective: The aim of this article is to review the current state of the art of CSU, the real-life experience with omalizumab and the promising drugs that are under development. Methods:: An electronic search was performed to identify studies, case reports, guidelines and reviews focused on the new targets for the treatment of chronic spontaneous urticaria, both approved or under investigation. The search was limited to articles published in peer-reviewed journals in the English Language in the PubMed database and trials registered in Clinicaltrials.gov. Results:: Since the advent of omalizumab, the search for new therapies for chronic spontaneous urticaria has had a new impulse. Anti-IgE drugs will probably still be the cornerstone of therapy, but new targets may prove effective in syndromic urticaria or refractory cases. Conclusion:: Although omalizumab has been a breakthrough in the treatment of CSU, many patients do not completely get benefit and even require more effective treatments. Novel drugs are under investigation with promising results.

7 November 2024 in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
Verified
Journal Article
Closed access
GDGiovanni Marco D'AGostino
Giovanni Marco D'AGostino
TBTommaso Bianchelli
Tommaso Bianchelli
AGAlfredo Giacchetti
Alfredo Giacchetti
DBDonatella Brancorsini
Donatella Brancorsini